{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"NeuroSense Issues CEO Letter to Shareholders - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"5DyHyDQr8A\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurosense-issues-ceo-letter-to-shareholders\/\">NeuroSense Issues CEO Letter to Shareholders<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurosense-issues-ceo-letter-to-shareholders\/embed\/#?secret=5DyHyDQr8A\" width=\"600\" height=\"338\" title=\"&#8220;NeuroSense Issues CEO Letter to Shareholders&#8221; &#8212; Market Newsdesk\" data-secret=\"5DyHyDQr8A\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"PR Newswire CAMBRIDGE, Mass., Aug. 13, 2026 \/PRNewswire\/ &#8212;\u00a0NeuroSense Therapeutics Ltd.\u00a0(NASDAQ: NRSN) (&#8220;NeuroSense&#8221;), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, Alon Ben-Noon, to investors. \u00a0 \u00a0 Dear Fellow Shareholders, I wanted to take this opportunity to update you on NeuroSense&#8217;s\u00a0 preparations for the Phase 3 PARAGON study, our efforts to secure the resources needed to advance it, the regulatory opportunities we are pursuing in Canada and other territories, the strategic discussions under way, and our work on Nasdaq compliance. Our main focus is PARAGON, our pivotal Phase 3 study of PrimeC in ALS. The FDA has cleared NeuroSense to initiate PARAGON, which is expected to enroll approximately &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/mma.prnewswire.com\/media\/1707291\/NeuroSense_Therapeutics_Logo.jpg"}